glp-1 agonist drugs oral receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is GLP-1 medicines started with injectable

While lifestyle modifications such as dietary changes, increased physical activity, and behavioral therapy remain the foundation of treatment, their long-term effectiveness is often limited, especially in cases of severe obesity

[263] proved that miR-7 controls the release of insulin mediated by GLP-1 by aiming at -Arrestin 1 (ARR1)

Enhanced GIP secretion in obesity is associated with biochemical alteration and miRNA contribution to the development of liver steatosis

In clinical practice, unique factors often drive therapeutic decisions that are made by patients, HCPs, or both

But she pointed to the associations Principles of Practice, which states that telehealth business models must put the patient first. Proceed with caution Pharmaceutical companies must list potentially harmful side effects when they advertise the name-brand versions of their FDA-approved medications

We present this article in accordance with the Narrative Review reporting checklist (available at Methods A search of the literature was conducted on OVID (1947May 2025) using the terms [papilledema OR intracranial hypertension OR idiopathic intracranial hypertension OR brain pseudotumor] AND [glucagon like peptide 1 OR glucagon like peptide 1 receptor agonist OR semaglutide OR exendin 4 OR liraglutide OR tirzepatide]